Miscellaneous topics

Breast cancer risk assessment in indigent women at a public hospital.
Abu-Rustum NR, Herbolsheimer H. Gynecol Oncol. 2001;81:287-90.

Alcohol exposure in utero and breast cancer risk later in life.
Stevens RG, Hilakivi-Clarke L.  Alcohol. 2001;36:276-7

Abortion history and breast cancer risk: Results from the Shanghai breast cancer study.
Sanderson M, Shu XO, Jin F, et al.  Int J Cancer. 2001;92:899-905.

Lobular carcinoma in situ increases the risk of local recurrence in selected patients with stages I and II breast carcinoma treated with conservative surgery and radiation.
Sasson AR, Fowble B, Hanlon AL, et al.  Cancer. 2001;91:1862-9.

Serum enterolactone and risk of breast cancer: a case-control study in eastern finland.
Pietinen P, Stumpf K, Mannisto S, Kataja V, Uusitupa M, Adlercreutz H.  Cancer Epidemiol Biomarkers Prev. 2001;10:339-44.

Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ. 
Bijker N, Peterse JL, Duchateau L, et al. British Journal of Cancer. 84(4):539-544, 2001 Feb.

Breast cancer risk in relation to amount of tissue removed during breast reduction operations in Sweden.
Brinton LA, Persson I, Boice JD, McLaughlin JK, Fraumeni JF.  Cancer. 91(3):478-483, 2001 Feb 1.

Radiation-induced chromatid breaks as a predictor of breast cancer risk.
Buchholz TA, Wu XF.  International Journal of Radiation Oncology, Biology, Physics. 49(2):533-537, 2001 Feb 1.

Effects of mammographic density and benign breast disease on breast cancer risk (United States).
Byrne C, Schairer C, Brinton LA, et al. Cancer Causes & Control. 12(2):103-110, 2001 Feb.

Tubal sterilization and risk of breast cancer mortality in US women.
Petrelli JM, Thun MJ.Calle EE, Rodriguez C, Walker KA, Wingo PA,  Cancer Causes & Control. 12(2):127-135, 2001 Feb.

Building a multigenic model of breast cancer susceptibility: CYP17 and HSD17B1 are two important candidates. 
Feigelson HS, McKean-Cowdin R, Coetzee GA, Stram DO, Kolonel LN, Henderson BE. Cancer Research. 61(2):785-789, 2001 Jan 15.

Breast cancer risk assessment in indigent women at a public hospital.
Abu-Rustum NR, Herbolsheimer H. Gynecol Oncol. 2001;81:287-90.

Being breastfed in infancy and breast cancer incidence in adult life: Results from the two nurses' health studies.
Michels KB, Trichopoulos D, Rosner BA, et al.  American Journal of Epidemiology. 153(3):275-283, 2001 Feb 1.

Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers.
Nichols KE, Malkin D, Garber JE, Fraumeni JF, Li FP.  Cancer Epidemiology, Biomarkers & Prevention. 10(2):83-87, 2001 Feb.

Breast cancer, occupation, and exposure to electromagnetic fields among Swedish men. 
Pollan M, Gustavsson P, Floderus B. American Journal of Industrial Medicine. 39(3):276-285, 2001 Mar.

The role of psychosocial factors in the development of breast carcinoma: Part II - Life event stressors, social support, defense style, and emotional control and their interactions.
Price MA, Tennant CC, Butow PN, et al.  Cancer. 91(4):686-697, 2001 Feb 15.

Risk of breast cancer in female flight attendants: a population-based study (Iceland).
Rafnsson V, Tulinius H, Jonasson JG, Hrafnkelsson J.  Cancer Causes & Control. 12(2):95-101, 2001 Feb.

Long-term cancer risk in women given diethylstilbestrol (DES) during pregnancy. 
Titus-Ernstoff L, Hatch EE, Hoover RN, et al. British Journal of Cancer. 84(1):126-133, 2001 Jan 5.

Circulating levels of sex hormones and their relation to risk factors for breast cancer: a cross-sectional study in 1092 pre- and postmenopausal women (United Kingdom).
Verkasalo PK, Thomas HV, Appleby PN, Davey GK, Key TJ.  Cancer Causes & Control. 12(1):47-59, 2001 Jan.

Breast cancer risk and "delayed" primary Epstein-Barr virus infection.
Yasui Y, Potter JD, Stanford JL, et al.  Cancer Epidemiology, Biomarkers & Prevention. 10(1):9-16, 2001 Jan.

Cancer risk in Swedish women: the relation to size at birth.
Andersson SW, Bengtsson C, Hallberg L, et al.  Br J Cancer. 2001;84:1193-8.

Increased breast cancer risk among women who work predominantly at night.
Hansen J.  Epidemiology. 12(1):74-77, 2001 Jan.

Breast cancer risk assessment in indigent women at a public hospital.
Abu-Rustum NR, Herbolsheimer H.  Gynecol Oncol. 2001;81:287-90.

Age at any birth is associated with breast cancer risk. 
Wohlfahrt J, Melbye M. Epidemiology. 12(1):68-73, 2001 Jan.

Chromosomal radiosensitivity as a marker of predisposition to common cancers?
Baria K, Warren C, Roberts SA, West CM, Scott D.  Br J Cancer. 2001;84:892-6.

Effects of mammographic density and benign breast disease on breast cancer risk (United States). 
Byrne C, Schairer C, Brinton LA, et al. Cancer Causes & Control. 12(2):103-110, 2001 Feb.

Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention.
Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA.  J Natl Cancer Inst. 93(5):358-366, 2001

Effects of mammographic density and benign breast disease on breast cancer risk (United States).
Byrne C, Schairer C, Brinton LA, et al.  Cancer Causes & Control. 12(2):103-110, 2001 Feb.

Bone mineral density and breast cancer risk in postmenopausal women. 
Buist DS, LaCroix AZ, Barlow WE, White E, Weiss NS. J Clin Epidemiol. 2001;54:417-22.

Highly proliferative fibroblasts forming fibrotic focus govern metastasis of invasive ductal carcinoma of the breast.
Hasebe T, Sasaki S, Imoto S, Ochiai A.  Mod Pathol. 2001;14:325-37.

Saliva as a medium for investigating intra- and interindividual differences in sex hormone levels in premenopausal women.
Gann PH, Giovanazzi S, Van Horn L, Branning A, Chatterton RT.  Cancer Epidemiology, Biomarkers & Prevention. 10(1):59-64, 2001 Jan.

Fibroadenoma of the breast. Medical Journal of Australia. 
Houssami N, Cheung MNK, Dixon JM. 174(4):185-188, 2001 Feb 19.

Pathologic features of breast cancers in women with previous benign breast disease.
Jacobs TW, Byrne C, Colditz G, Connolly JL, Schnitt SJ.  American Journal of Clinical Pathology. 115(3):362-369, 2001 Mar.

Atypical lobular hyperplasia or lobular carcinoma in situ at core-needle breast biopsy.
Berg WA, Mrose HE, Ioffe OB.  Radiology. 218(2):503-509, 2001 Feb.

Atypical lobular hyperplasia or lobular carcinoma in situ at core-needle breast biopsy.
Berg WA, Mrose HE, Ioffe OB.  Radiology. 218(2):503-509, 2001 Feb.

Comparisons of two breast cancer risk estimates in women with a family history of breast cancer. 
McTiernan A, Kuniyuki A, Yasui Y, et al. Cancer Epidemiol Biomarkers Prev. 2001;10:333-8.

The risk of developing breast cancer within the next 5, 10, or 20 years of a woman's life.
Morris CR, Wright WE, Schlag RD.  Am J Prev Med. 2001;20:214-8.

Chemoprevention of breast cancer

Safety of the synthetic retinoid fenretinide: long-term results from a controlled clinical trial for the prevention of contralateral breast cancer.
Camerini T, Mariani L, De Palo G, et al.  J Clin Oncol. 2001;19:1664-70.

Chemoprevention of breast cancer.
Dalton RR, Kallab AM.  Southern Medical Journal. 94(1):7-15, 2001 Jan.

Aromatase inhibitors in the treatment and prevention of breast cancer [Review]. 
Goss PE, Strasser K. Journal of Clinical Oncology. 19(3):881-894, 2001 Feb 1.

Effects of chemopreventive and antitelomerase agents on the spontaneous immortalization of breast epithelial cells.
Herbert BS, Wright AC, Passons CM, et al. J Natl Cancer Inst. 93(1):39-45, 2001 Jan 3. 

Peroxisome proliferator-activated receptors: roles in tumorigenesis and chemoprevention in human cancer [Review]. 
Park BH, Breyer B, He TC.Current Opinion in Oncology. 13(1):78-83, 2001 Jan.

Cardiovascular effects of tamoxifen in women with and without heart disease: Breast cancer prevention trial. 
Reis SE, Costantino JP, Wickerham DL, Tan-Chiu E, Wang JP, Kavanah M. J Natl Cancer Inst. 93(1):16-21, 2001 Jan 3.

Nutrition and breast cancer prevention

Types of dietary fat and breast cancer: a pooled analysis of cohort studies.
Smith-Warner SA, Spiegelman D, Adami HO, et al.  Int J Cancer. 2001;92:767-74.

Soyfood Intake during Adolescence and Subsequent Risk of Breast Cancer among Chinese Women. 
Shu XO, Jin F, Dai Q, et al. Cancer Epidemiol Biomarkers Prev. 2001;10:483-8.

A prospective study of obesity and cancer risk (Sweden). 
Wolk A, Gridley G, Svensson M, et al. Cancer Causes & Control. 12(1):13-21, 2001 Jan.

Genetics, hereditary breast cancer

Founder BRCA1 and BRCA2 mutations in early-onset French Canadian breast cancer cases unselected for family history.
Tonin PN, Perret C, Lambert JA, et al. Int J Cancer. 2001;95:189-93.

BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. 
Welcsh PL, King MC. Hum Mol Genet. 2001;10:705-13.

The lifetime risks of breast cancer in ashkenazi jewish carriers of brca1 and brca2 mutations. 
Satagopan JM, Offit K, Foulkes W, et al. Cancer Epidemiol Biomarkers Prev. 2001;10:467-73.

Brca1/2 testing: complex themes in result interpretation.
Peshkin BN, DeMarco TA, Brogan BM, Lerman C, Isaacs C.  J Clin Oncol. 2001;19:2555-65.

Colorado family physicians' knowledge of hereditary breast cancer and related practice.
Mouchawar J, Klein CE, Mullineaux L. J Cancer Educ. 2001;16:33-7.

Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. 
Brekelmans CTM, Seynaeve C, Bartels CCM, et al. Journal of Clinical Oncology. 19(4):924-930, 2001 Feb 15.

'Other' breast cancer susceptibility genes: searching for more holy grail. 
Nathanson KL, Weber BL. Hum Mol Genet. 2001;10:715-20.

Breast cancer genetics: What we know and what we need.
Nathanson KN, Wooster R, Weber BL. Nat Med. 2001;7:552-6.

Educational review: role of the surgeon in hereditary breast cancer. 
Newman LA, Kuerer HM, Hunt KK, et al. Ann Surg Oncol. 2001;8:368-78.

Absence of rearrangements in the BRCA2 gene in human cancers. 
Chin SF, Wang Q, Puisieux A, Caldas C. British Journal of Cancer. 84(2):193-195, 2001 Jan 19.

How women with a family history of breast cancer and their general practitioners act on genetic advice in general practice: prospective longitudinal study.
de Bock GH, van Asperen CJ, de Vries JM, Hageman GCHA, Springer MP, Kievit J. BMJ. 322(7277):26-27, 2001 Jan 6.

After BRCA1 and BRCA2-what next? Multifactorial segregation analyses of three-generation, population-based Australian families affected by female breast cancer. 
Cui JS, Antoniou AC, Dite GS, et al. American Journal of Human Genetics. 68(2):420-431, 2001 Feb.

How women with a family history of breast cancer and their general practitioners act on genetic advice in general practice: prospective longitudinal study. 
de Bock GH, van Asperen CJ, de Vries JM, Hageman GCHA, Springer MP, Kievit J. BMJ. 322(7277):26-27, 2001 Jan 6.

Genetic testing for cancer predisposition [Review]. 
Eng C, Hampel H, de la Chapelle A. Annual Review of Medicine. 52:371-400, 2001.

Hereditary cancer syndromes. 
Frank TS. Archives of Pathology & Laboratory Medicine. 125(1):85-90, 2001 Jan.

BRCA1 function in T lymphocytes: a cellular specificity of a different kind [Review]. 
Gardner K, Liu ET. Breast Cancer Research. 3(1):11-13, 2001.

Genetic testing for inherited breast and ovarian cancer syndromes: important concepts for the primary care physician [Review].
Taylor MRG. Postgraduate Medical Journal. 77(903):11-15, 2001 Jan.

Gene-expression profiles in hereditary breast cancer. 
Hedenfalk I, Duggan D, Chen YD, et al. New England Journal of Medicine. 344(8):539-548, 2001 Feb 22.

Implications of oncogenomics for cancer research and clinical oncology. 
Herrmann JL, Rastelli L, Burgess CE, et al. Cancer Journal. 7(1):40-51, 2001 Jan-Feb.

Genetic testing for inherited breast and ovarian cancer syndromes: important concepts for the primary care physician [Review].
Taylor MRG. Postgraduate Medical Journal. 77(903):11-15, 2001 Jan.

Coping with grim news from genetic tests. 
Horowitz M, Sundin E, Zanko A, Lauer R. Psychosomatics. 42(2):100-105, 2001 Mar-Apr.

Germ line mutations associated with breast cancer susceptibility [Review]. 
Iau PTC, Macmillan RD, Blamey RW. European Journal of Cancer. 37(3):300-321, 2001 Feb.

Splice variant expression of CD44 in patients with breast and ovarian cancer. 
Lockhart MS, Hajos SE, Basilio FM, Mongini C, Alvarez E. Oncology Reports. 8(1):145-151, 2001 Jan-Feb.

Genetic variation in the tumor necrosis factor-alpha promoter region and in the stress protein hsp70-2 - Susceptibility and prognostic implications in breast carcinoma. 
Mestiri S, Bouaouina N, Ben Ahmed S, et al. Cancer. 91(4):672-678, 2001 Feb 15.

An association between cartilaginous tumours and breast cancer in the national pathology registration in The Netherlands points towards a possible genetic trait.
Odink AE, van Asperen CJ, Vandenbroucke JP, Cleton-Jansen AM, Hogendoom PCW. Journal of Pathology. 193(2):190-192, 2001 Feb.

Screening of male breast cancer and of breast-ovarian cancer families for BRCA2 mutations using large bifluorescent amplicons. 
Pages S, Caux V, Stoppa-Lyonnet D, Tosi M. British Journal of Cancer. 84(4):482-488, 2001 Feb.

Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. 
Risch HA, McLaughlin JR, Cole DEC, et al. American Journal of Human Genetics. 68(3):700-710, 2001 Mar.

Genetic testing for inherited breast and ovarian cancer syndromes: important concepts for the primary care physician [Review]. 
Taylor MRG. Postgraduate Medical Journal. 77(903):11-15, 2001 Jan.

Parental communication of BRCA1/2 genetic test results to children. 
Tercyak KP, Hughes C, Main D, et al. Patient Education & Counseling. 42(3):213-224, 2001 Mar.

Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. 
Thompson D, Easton D. American Journal of Human Genetics. 68(2):410-419, 2001 Feb.

De novo recurrent germline mutation of the BRCA2 gene in a patient with early onset breast cancer. 
van der Luijt RB, van Zon PHA, Jansen RPM, van der Sijs-Bos CJM, Warlam-Rodenhuis CC, Ausems MGEM. Journal of Medical Genetics. 38(2):102-105, 2001 Feb.

Nonhomologous end-joining of ionizing radiation-induced DNA double-stranded breaks in human tumor cells deficient in BRCA1 or BRCA2. 
Wang HC, Zeng ZC, Bui TA, et al. Cancer Research. 61(1):270-277, 2001 Jan 1.

A computer model to simulate family history of breast/ovarian cancer in BRCA1 mutation carriers. 
Bajdik CD, Raboud JM, Schechter MT, McGillivray BC, Gallagher RP. Math Biosci. 2001;171:99-111.

First BRCA1 and BRCA2 gene testing implemented in the health care system of Stockholm.
Arver B, Borg A, Lindblom A. Genet Test. 2001;5:1-8.

Modification of cancer risks in offspring by sibling and parental cancers from 2,112,616 nuclear families.
Dong C, Hemminki K.  Int J Cancer. 2001;92:144-50.

Identifying women at risk for inherited breast cancer using a mammography registry. 
Geller BM, Mickey RM, Rairikar CJ, McKinnon WC. J Cancer Educ. 2001;16:46-9.

Genetic susceptibility to breast cancer in French-Canadians: role of carcinogen-metabolizing enzymes and gene-environment interactions. 
Krajinovic M, Ghadirian P, Richer C, et al. Int J Cancer. 2001;92:220-5.

Cost of genetic counseling and testing for brca1 and brca2 breast cancer susceptibility mutations. 
Lawrence WF, Peshkin BN, Liang W, Isaacs C, Lerman C, Mandelblatt JS. Cancer Epidemiol Biomarkers Prev. 2001;10:475-81.

Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic. 
Martin AM, Blackwood MA, Antin-Ozerkis D, et al. J Clin Oncol. 2001;19:2247-53.

The BRCA1 syndrome and other inherited breast or breast-ovarian cancers in a Norwegian prospective series.
Moller P, Borg A, Heimdal K, et al.  Eur J Cancer. 2001;37:1027-32.

Hormone replacement and breast cancer risk

Correlates of hormone replacement therapy use in former users of oral contraceptives.
Frank E, Rock J, Elon L. Obstet Gynecol. 2001;97:S24.

Correlates of hormone replacement therapy use in former users of oral contraceptives.
Frank E, Rock J, Elon L. Obstet Gynecol. 2001;97:S24.

Increased incidence of small and well-differentiated breast tumours in post-menopausal women following hormone-replacement therapy. 
Manjer J, Malina J, Berglund G, Bondeson L, Garne JP, Janzon L. Int J Cancer. 2001;92:919-22.

Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. 
O'Meara ES, Rossing MA, Daling JR, Elmore JG, Barlow WE, Weiss NS. J Natl Cancer Inst. 2001;93:754-61.

Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy.
Rutter CM, Mandelson MT, Laya MB, Seger DJ, Taplin S.  Jama: Journal of the American Medical Association. 285(2):171-176, 2001 Jan 10.

Proliferative effects of combination estrogen and progesterone replacement therapy on the normal postmenopausal mammary gland in a murine model. 
Raafat AM, Hofseth LJ, Haslam SZ. American Journal of Obstetrics & Gynecology. 184(3):340-349, 2001 Feb.

Incidence of cancer among women using long versus monthly cycle hormonal replacement therapy, Finland 1994-1997. 
Pukkala E, Tulenheimo-Silfvast A, Leminen A. Cancer Causes & Control. 12(2):111-115, 2001 Feb.

Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk. 
Col NF, Hirota LK, Orr RK, Erban JK, Wong JB, Lau J. J Clin Oncol. 2001;19:2357-63.

Correlates of hormone replacement therapy use in former users of oral contraceptives. 
Frank E, Rock J, Elon L. Obstet Gynecol. 2001;97:S24.

Lifestyle and breast cancer prevention

Effect of ethanol on proliferation and estrogen receptor-alpha expression in human breast cancer cells. 
Singletary KW, Frey RS, Yan W. Cancer Lett. 2001;165:131-7.

Postmenopausal obesity as a breast cancer risk factor according to estrogen and progesterone receptor status (Japan). 
Yoo K, Tajima K, Park S, et al.Cancer Lett. 2001;167:57-63.

Lifetime physical activity and breast cancer risk in the Shanghai Breast Cancer Study. 
Matthews CE, Shu XO, Jin F, et al. Br J Cancer. 2001;84:994-1001.

Physical activity and cancer prevention: from observational to intervention research. 
Friedenreich CM. Cancer Epidemiol Biomarkers Prev. 2001;10:287-301.

Reducing bioavailable sex hormones through a comprehensive change in diet: the diet and androgens (DIANA) randomized trial. 
Berrino F, Bellati C, Secreto G, et al. Cancer Epidemiology, Biomarkers & Prevention. 10(1):25-33, 2001 Jan.

Macronutrient intake and estrogen metabolism in healthy postmenopausal women. 
Fowke JH, Longcope C, Hebert JR. Breast Cancer Research & Treatment. 65(1):1-10, 2001 Jan.

Vitamin D is a prooxidant in breast cancer cells. 
Koren R, Hadari-Naor I, Zuck E, Rotem C, Liberman UA, Ravid A. Cancer Research. 61(4):1439-1444, 2001 Feb 15.

Physical activity and breast cancer risk: The women's health study (United states). 
Lee IM, Rexrode KM, Cook NR, Hennekens CH, Buring JE. Cancer Causes & Control. 12(2):137-145, 2001 Feb.

Effects of acute and chronic body weight gain reductions in the evaluation of agents for efficacy in mammary cancer prevention. 
Rodriguez-Burford C, Lubet RA, Steele VE, et al. Oncology Reports. 8(2):373-379, 2001 Mar-Apr.

Intake of fruits and vegetables and risk of breast cancer - A pooled analysis of cohort studies [Review]. 
Smith-Warner SA, Spiegelman D, Yaun SS, et al. Jama: Journal of the American Medical Association. 285(6):769-776, 2001 Feb 14.

Diet and cancer: One view at the start of the millennium. 
Willett WC. Cancer Epidemiology, Biomarkers & Prevention. 10(1):3-8, 2001 Jan.

Smoking during pregnancy and breast cancer risk in very young women (United States). 
Innes KE, Byers TE. Cancer Causes & Control. 12(2):179-185, 2001 Feb.

Cancer-related risk indicators and preventive screening behaviors among lesbians and bisexual women. 
Cochran SD, Mays VM, Bowen D, et al. Am J Public Health. 2001;91:591-7.

Cigarette Smoking Increases Risk for Breast Cancer in High-Risk Breast Cancer Families. 
Couch FJ, Cerhan JR, Vierkant RA, et al. Cancer Epidemiol Biomarkers Prev. 2001;10:327-332.

Serum hormones and the alcohol-breast cancer association in postmenopausal women. 
Dorgan JF, Baer DJ, Albert PS, et al. J Natl Cancer Inst. 2001;93:710-5.

Alcohol and breast cancer mortality in a cohort study. 
Jain MG, Ferrenc RG, Rehm JT, et al. Breast Cancer Res Treat. 2001;64:201-9.

Stress of daily activities and risk of breast cancer: a prospective cohort study in Finland. 
Lillberg K, Verkasalo PK, Kaprio J, Teppo L, Helenius H, Koskenvuo M. Int J Cancer. 2001;91:888-93.

Prophylactic mastectomies

The psychosocial impact of bilateral prophylactic mastectomy: prospective study using questionnaires and semistructured interviews.
Hatcher MB, Fallowfield L, A'Hern R. BMJ. 322(7278):76-79, 2001 Jan 13.

Pathogenesis of breast cancer

Do urinary estrogen metabolites reflect the differences in breast cancer risk between Singapore Chinese and United States African-American and white women? 
Ursin G, Wilson M, Henderson BE, et al. Cancer Res. 2001;61:3326-9.

New advances in the understanding of the role of steroids and steroid receptors in disease.
Wiseman H, Duffy R. Biochem Soc Trans. 2001;29:205-9.

Nerve Growth Factor Stimulates Proliferation and Survival of Human Breast Cancer Cells through Two Distinct Signaling Pathways. 
Descamps S, Toillon RA, Adriaenssens E, et al. J Biol Chem. 2001;276:17864-17870.

Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells. 
Badache A, Hynes NE. Cancer Research. 61(1):383-391, 2001 Jan 1.

Three down and counting: the transformation of human mammary cells from normal to malignant in three steps. 
Barcellos-Hoff MH. Trends Mol Med. 2001;7:142-3.

Molecular cytogenetic comparison of apocrine hyperplasia and apocrine carcinoma of the breast. 
Jones C, Damiani S, Wells D, Chaggar R, Lakhani SR, Eusebi V. American Journal of Pathology. 158(1):207-214, 2001 Jan.

Estrogen receptor beta expression in invasive breast cancer. 
Mann S, Laucirica R, Carlson N, et al. Human Pathology. 32(1):113-118, 2001 Jan.

Nuclear cytometric changes in breast carcinogenesis. 
Mommers ECM, Poulin N, Sangulin J, Meijer CJLM, Baak JPA, van Diest PJ. Journal of Pathology. 193(1):33-39, 2001 Jan.

Polyunsaturated fatty acids and epidermal growth factor receptor/mitogen-activated protein kinase signaling in mammary cancer. 
Cowing BE, Saker KE. J Nutr. 2001;131:1125-8.

Interferon regulatory factor expression in human breast cancer.
Doherty GM, Boucher L, Sorenson K, Lowney J. Ann Surg. 2001;233:623-9.

p53 missense mutations in microdissected high-grade ductal carcinoma in situ of the breast. 
Done SJ, Eskandarian S, Bull S, Redston M, Andrulis IL. J Natl Cancer Inst. 2001;93:700-4.

Enrichment of memory T cells and other profound immunological changes in the bone marrow from untreated breast cancer patients. 
Feuerer M, Rocha M, Bai L, et al. Int J Cancer. 2001;92:96-105.

The role of hormones in breast carcinogenesis: Issues of relevance to female childhood cancer survivors. 
Ganz PA. Med Pediatr Oncol. 2001;36:514-8.

Growth hormone receptor is expressed in human breast cancer. 
Gebre-Medhin M, Kindblom LG, Wennbo H, Tornell J, Meis-Kindblom JM. Am J Pathol. 2001;158:1217-22.

TP53 Mutations in Breast Cancer Associated with BRCA1 or BRCA2 Germ-line Mutations: Distinctive Spectrum and Structural Distribution. 
Greenblatt MS, Chappuis PO, Bond JP, Hamel N, Foulkes WD. Cancer Res. 2001;61:4092-7.

Estrogen response element sequence impacts the conformation and transcriptional activity of estrogen receptor alpha(1).
Klinge CM, Jernigan SC, Smith SL, Tyulmenkov VV, Kulakosky PC.  Mol Cell Endocrinol. 2001;174:151-66.

Correlation between angiogenesis, apoptosis and cell proliferation in invasive ductal carcinoma of the breast and their relation to tumor behavior. 
Lee JS, Kim HS, Jung JJ, Kim YB, Park CS, Lee MC. Anal Quant Cytol Histol. 2001;23:161-8.